<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
BioNTech SE BNTX, -1.36% and Regeneron Pharmaceuticals Inc. REGN, -0.58% said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron’s Libtayo in patients with advanced non-small cell lung cancer, starting with a Phase 1/2 clinical trial. Libtayo is approved in the U.S. to treat advanced basal cell carcinoma.
...read full article on Market Watch
